Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Cymbalta Prescribers for Neuropathic Pain (US)

Articles with lock require a subscription to GLG News | Request a free trial
August 30, 2007
Looking forward to Vical Phase 1 Trial of H5N1
Analysis of: Vical Begins Phase 1 Trial Of DNA Vaccine Against H5N1 Pandemic Influenza | www.medicalnewstoday.com
Author: GLG Expert Contributor
I'm looking forward to the results of the H5N1 clincial trial.  This might improve the world's chances of avoiding a pandemic like the one in 1918.
August 21, 2007
Avandia And The Story Of Humpty Dumpty
Analysis of: GlaxoSmithKline updates prescribing information for Avandia in the US | www.pipelinereview.com
Author: GLG Expert Contributor
The Black Box CHF Warning for Avandia and Actos, is not new information. It merely defects the real issue-- the risk of overall cardiac events.
August 20, 2007
Vertebroplasty vs kyphoplasty vs arcuoplasty
Analysis of: Medtronic Buys Kyphon For $3.9 Billion | www.forbes.com
Author: Luc Jasmin, Attending Neurosurgeon and a Research Scientist, Cedars-Sinai Medical Center
Will the recent purchase of Kyphon by Medtronic signals the end of kyphoplasty? No because arcuoplasty does not restore vertebral height. Vertebroplasty, kyphoplasty and arcuoplasty essentially achieve the same goals, which brings up the question, do we need all three techniques? Arcuoplasty is the...
August 16, 2007
Keep Drinking Soft Drinks, and Keep the Diabetes Industry Alive!
Analysis of: Framingham Observational Study Notes Greater Incidence Of Metabolic Syndrome Among Adults Consuming Soft Drinks | www.medicalnewstoday.com
Author: GLG Expert Contributor
People, in general, who may have other concerns than their health, consume soft drinks, both regular and diet. High fructose corn syrup in our society is like lead to the Romans. Why is taking our government so long to figure this out?
August 13, 2007
Changing the supply and demand curve for primary care
Analysis of: Doctor Shortage Hurts A Coverage-for-All Plan | online.wsj.com
Author: GLG Expert Contributor
Improving patient access to health care is needed. In Massachusetts, the supply and demand curve in primary care has changed.  How quickly can market forces recover?
July 30, 2007
Bristol-Myers Diabetes Drug, A Novel Mechanism, A Long Road To Haul
Analysis of: Bristol-Myers Drug, First in New Family, Controls Blood Sugar | www.bloomberg.com
Author: GLG Expert Contributor
Dapagliflozin has a long way to go to prove its efficacy and safety as a potential diabetes medication. However, innovative medications are welcome as they will be pieces of the diabetic solution puzzle.
July 25, 2007
Galvus is way behind the eight ball in diabetes care.
Analysis of: Galvus(R), a new oral treatment for type 2 diabetes, receives positive opinion recommending European Union approval | www.pipelinereview.com
Author: GLG Expert Contributor
Galvus does not seem to have a competitive edge over Januvia, its main competition. Galvus needs to demonstrate a yet unknown significant advantage to gain significant market share.
July 19, 2007
Older diabetic medications are far from being adequate
Analysis of: Older and cheaper pills just fine for diabetes | www.reuters.com
Author: GLG Expert Contributor
Long-term comparisons of glycemic control are lacking between newer and older diabetes medications. However this is a one-dimensional comparison. Newer medications have significant other advantages over the older medications, but both are needed to safely reach glycemic goals.
July 9, 2007
Alzheimer's drug patch could change quality of life
Analysis of: UPDATE: Novartis Wins FDA OK For Alzheimer's Drug Patch | money.cnn.com
Author: GLG Expert Contributor
Alzheimer's drug patch could change quality of life of the patient and their family. Usually patients with Alzheimer's disease have more than one disease and takes three up to fifteen different medications a day. Long span release patches are very convenient to this patients for many reasons, not only...
July 9, 2007
Eliminating Pharmaceutical detailing: Throwing at the baby with the bath water.
Analysis of: UPMC draws up severe code on freebies | www.post-gazette.com
Author: GLG Expert Contributor
Unilateral decisions about pharmaceutical detailing makes policy makers feel good, but the bottom line, the patients, are the ones that could pay.

Previous Page : 1 2 3 4 5 6 7 Next21 to 30 of 68

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-02T17:45:17.163